TriSol Medical

Percutaneous Tricuspid Valve Replacement

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in July 2016, TriSol Medical operates with 11–50 employees. The company has raised $31.43M across 4 funding rounds from 3 investors. In July 2023, the European Innovation Council participated in a funding round.

Business overview

TriSol Medical is a Health Tech & Life Sciences company focused on developing a best-in-class transcatheter tricuspid replacement valve. Its core technology is a unique device designed to eliminate tricuspid regurgitation while preserving right ventricle function. The company serves the medical devices market, specifically targeting patients with severe tricuspid regurgitation.

Strategic signal

In January 2026, TriSol Medical announced positive results from a US early feasibility study of its transcatheter tricuspid valve replacement system. This signals significant progress in the clinical development and potential market validation of its innovative medical device, indicating a strong forward trajectory for the company in the cardiovascular treatment sector.

Company Intelligence Q&A

What is TriSol Medical's primary focus?
TriSol Medical is dedicated to developing a transcatheter tricuspid valve replacement system designed to eliminate tricuspid regurgitation while preserving right ventricle function.
When was TriSol Medical founded?
TriSol Medical was founded in July 2016.
What was a key development for TriSol Medical in January 2026?
In January 2026, TriSol Medical announced positive results from a US early feasibility study of its transcatheter tricuspid valve replacement system.
Which investor participated in a funding round in July 2023?
In July 2023, the European Innovation Council participated in a funding round for TriSol Medical.
What was a significant milestone for TriSol Medical in August 2023?
In August 2023, TriSol Medical announced successful implants of its Transcatheter Tricuspid Valve in the US.

External links